REQUEST A DEMO
Total
USD $0.00
Search more companies

PT Tunggal Idaman Abdi (Indonesia)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: PT Tunggal Idaman Abdi Profile Updated: November 25, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

PT Tunggal Idaman Abdi is an Indonesian pharmaceutical company that specializes in reproductive healthcare and offers affordable contraceptives at international quality standards. PT Tunggal Idaman Abdi manufactures Triclofem, a three monthly injectable contraceptive that has been awarded WHO PQ status in 2021. The company supplies quality products to both private and public sectors in domestic and overseas markets, with a network of sales representatives across Indonesia.

Headquarters
RT 012 RW 006
East Jakarta; Jakarta; Postal Code: 13230

Contact Details: Purchase the PT Tunggal Idaman Abdi report to view the information.

Website: http://www.tunggal-pharma.com

Basic Information
Total Employees:
Purchase the PT Tunggal Idaman Abdi report to view the information.
Registered Capital:
Purchase the PT Tunggal Idaman Abdi report to view the information.
Financial Auditors:
Purchase the PT Tunggal Idaman Abdi report to view the information.
Incorporation Date:
December 21, 1983
Key Executives
Purchase this report to view the information.
President Director
Purchase this report to view the information.
President Commissioner
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Ownership Details
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Purchase this report to view the information.
Company Performance
Financial values in the chart are available after PT Tunggal Idaman Abdi report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency IDR. Absolute financial data is included in the purchased report.
Net sales revenue
13.63%
Total operating revenue
13.63%
Total Assets
13.8%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?